^
Association details:
| Biomarker: | NRAS mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | buparlisib (AN2025) (PI3K inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo
Excerpt:
We used human metastatic melanoma cell lines, which were BRAF-mutant (WM3734, 451Lu, A375, SKMel19), NRAS-mutant (SKMel147, WM1346, WM1366, MelJuso)….The MEK inhibitor binimetinib alone inhibited proliferation by 50% to 60% in the BRAF- and NRAS-mutated...
DOI:
10.1158/1078-0432.CCR-16-0064
